Paritosh Shah
Papers
1
Total Citations
12
H-Index
1
About
Paritosh Shah is a leading clinical researcher in ophthalmology, with a primary focus on neovascular age-related macular degeneration (nAMD), a leading cause of blindness worldwide. His most significant contribution is his pivotal role in the STAR trial, a rigorous, randomised, double-masked, sham-controlled device study published in 2024. This landmark investigation demonstrated that stereotactic radiotherapy can effectively mitigate key pathogenic processes underlying nAMD, offering a potential non-invasive alternative or adjunct to the standard-of-care anti-VEGF injections. By showing that precisely targeted ionising radiation reduces the treatment burden of frequent intravitreal injections, Shah’s work addresses a critical unmet need in retinal disease management. His research has garnered over a dozen citations in a short time, reflecting its immediate impact on clinical practice and device development. Shah’s achievements exemplify how translational research can directly improve patient quality of life, making him a notable figure in the evolving landscape of ophthalmic therapeutics.
Research Focus
Key Achievements
Top Papers
- 1